Clinical Trial Update: Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated Sofosbuvir plus Ribavirin for 12 or 24 weeks in treatment-naive and treatment-experienced Egyptian adults with chronic genotype 4 hepa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ribavirin (ribavirin)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus | Phase 3 | Status: COMPLETED | Results posted: 2015-05-22